Treatments, options and pricing
-
Initial consultation with GP 15 Minutes: £65
In this cancer screening initial consultation you will meet with a healthcare professional to discuss your medical history, assess your risk factors, and determine the most appropriate screening test for your individual circumstances.
-
Breast, Ovarian, Endometrial and Cervical Cancer Screening Test (Trucheck Female Health Cancer Screening Test) Price on Enquiry
Criteria for suitability: Women who have missed their recommended smear test or screening mammogram, Totally asymptomatic at present, All women above 40 years of age, No prior history of diagnosis or treatment of any cancer, No clinical or radiological suspicion of cancer at present.
Common Q&A about Women’s Cancer Screening Test (Trucheck FemmeSafe)
Our FAQ section is designed to address common questions you may have, from how our treatments work to what you can expect during and after your session.
Our team is always available to provide additional support if you need more personalised guidance, ensuring that you feel informed and confident every step of the way.
Trucheck FemmeSafe is a non-invasive blood test designed to detect early signs of cancer in women. It focuses on screening for multiple types of cancers, particularly those that are common in women, such as breast, ovarian, cervical, and uterine cancers.
Trucheck FemmeSafe detects cancer by analyzing circulating tumour cells (CTCs) and other biomarkers in the blood. It looks for abnormal cells that are shed by tumours into the bloodstream, helping identify cancer at an early stage.
This test primarily screens for breast, ovarian, uterine (endometrial), cervical, and other gynaecological cancers. It is designed to aid early detection when treatment can be most effective.
Women over the age of 30 or those with a family history of cancer are recommended to consider Trucheck FemmeSafe. It is also suggested for individuals with certain genetic predispositions or those at higher risk for developing gynaecological cancers.
Yes, Trucheck FemmeSafe is a completely safe, non-invasive test. It only requires a blood sample, making it a low-risk procedure with no exposure to radiation or harmful chemicals.
Trucheck FemmeSafe offers high sensitivity and specificity in detecting cancer, but like any screening test, it is not 100% accurate. It can provide early detection, but a positive result would require further diagnostic tests to confirm the presence of cancer.
It is generally recommended to undergo the test annually, particularly for women over 30 or those with risk factors for cancer. However, your healthcare provider may recommend different screening intervals based on your medical history.
If the test indicates a positive result, it means that abnormal cells potentially related to cancer were detected. Follow-up diagnostic tests, such as imaging or biopsy, will be necessary to confirm the presence and type of cancer.
Yes, Trucheck FemmeSafe is designed to detect cancers at early stages, often before symptoms appear. Early detection increases the likelihood of successful treatment and better outcomes.
Insurance coverage may vary depending on the provider and the country you are in. It's recommended to check with your insurance company to determine if they cover this test or offer reimbursement.
